Development of novel cell and gene therapies

细胞处理实验室正在开发新的自然杀伤（NK）细胞，树突状细胞（DC），骨髓基质细胞（BMSC）和嵌合抗原受体（CAR）T细胞疗法。 NK细胞是先天免疫系统的重要组成部分，并且它们被认为在宿主防御外来和异常细胞（包括癌症和血液恶性肿瘤）中起重要作用。初步工作表明，血液恶性肿瘤可以通过施用NK细胞来治疗。细胞处理实验室一直在扩大自体和同种异体NK细胞，以治疗临床中心的癌症和血液恶性肿瘤患者。 树突状细胞（Dendritic cells，DC）是肿瘤疫苗的重要佐剂。细胞处理实验室目前正在生产表达HER 2/neu的DC，以治疗肿瘤表达这种抗原的癌症患者，并正在开发一种治疗0期前列腺癌患者的新方案 骨髓基质细胞（BMSCs）具有抑制功能和支持组织再生的作用。此外，BMSCs分泌细胞因子和生长因子，促进受损组织的愈合，BMSCs已用于治疗缺血性心脏病和外周血管疾病患者。细胞处理实验室已经开发了一个从健康受试者中收集的BMSC产品库，用于治疗患有急性移植物抗宿主病或移植物衰竭和炎症性肠病的造血干细胞移植患者。该实验室还开发了一种生产自体BMSC的方法，用于治疗缺血性心脏病患者。 细胞处理实验室已经开发出表达抗CD 19的CAR T细胞。这些细胞现在被用于治疗患有B细胞白血病的儿科患者。该实验室还开发并正在生产抗GD 2 CAR T细胞，用于治疗肉瘤患者，抗B细胞成熟抗原（BCMA）用于治疗多发性骨髓瘤患者。一种生产抗CD 22 CAR T细胞的方法正在开发中。

The cell processing laboratory is developing new natural killer (NK) cell, dendritic cell (DC), bone marrow stromal cell (BMSC) and chimeric antigen receptor (CAR) T cell therapies. NK cells are an important part of the innate immune system and they are thought play an important in host defense against foreign and abnormal cells including cancer and hematological malignancies. Preliminary work suggests that hematological malignancies can be treated by the administration of NK cells. The Cell Processing Laboratory has been expanding autologous and allogeneic NK cells to treat Clinical Center patients with cancer and hematological malignancies. Dendritic cells (DCs) are an important adjuvant for cancer vaccines. The Cell Processing Laboratory is currently is producing DCs expressing HER2/neu to treat cancer patients whose tumor express this antigen and is developing a new protocol to treat patients with stage 0 prostate cancer Bone marrow stromal cells (BMSCs) can inhibit in function and support tissue regeneration Preliminary studies suggest that acute graft versus host disease and autoimmune diseases can be treated with BMSCs. In addition, BMSCs secrete cytokines and growth factor that improve the healing of damaged tissue and BMSCs have used to treat patients with ischemic heart disease and peripheral vascular disease. The Cell Processing Laboratory has developed a bank of BMSCs products collected from healthy subjects that is being used to treat hematopoietic stem transplant patients with acute graft versus host disease or graft failure and inflammatory bowel disease. The lab has also developed a process to produce autologous BMSCs to treat patients with ischemic heart disease. The cell processing laboratory has developed CAR T cells expressing anti-CD19. These cells are now being used to treat pediatric patents with B cell leukemias. The laboratory has also developed and is manufacturing anti-GD2 CAR T cells to treat patients with sarcoma and anti-B Cell Maturation Antigen (BCMA) to treat patients with multiple myeloma. A process to manufacture anti-CD22 CAR T cells in underdevelopment.